menu
    • menu

    Company profile for Janux Therapeutics

    NEW Drugs in Dev: 3
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Immunotherapy has ushered in a new era of cancer treatment with unprecedented responses in many patients. While a patient’s immune system should recognize and eliminate cancer, tumors have evolved a multitude of strategies to evade and dampen tumor immune surveillance. Immunotherapeutics overcome these tumor-generated obstacles and empower a patient’s immune system to recognize, attack, and eradicate the tumor. To take fu...
    Immunotherapy has ushered in a new era of cancer treatment with unprecedented responses in many patients. While a patient’s immune system should recognize and eliminate cancer, tumors have evolved a multitude of strategies to evade and dampen tumor immune surveillance. Immunotherapeutics overcome these tumor-generated obstacles and empower a patient’s immune system to recognize, attack, and eradicate the tumor. To take full advantage of modern immunotherapy, we need to increase the percentage of patients that respond to treatment. One way to increase the response rate is to more closely mimic a natural immune response.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Janux TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    11099 N. Torrey Pines Road, Suite 290 La Jolla, CA 92037
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.januxrx.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Natural Product Expo West

    Natural Product Expo West

    Not Confirmed

    envelop Contact Supplier

    Natural Product Expo West

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Janux Announces First Patient Dosed in Phase 1 Study of JANX011
    Janux Announces First Patient Dosed in Phase 1 Study of JANX011

    17 Feb 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260217098643/en/Janux-Therapeutics-Announces-First-Patient-Dosed-in-Phase-1-Study-of-JANX011

    BUSINESSWIRE
    17 Feb 2026
    Share Share
    Janux Pharma Names William Go, M.D., Ph.D., Chief Medical Officer
    Janux Pharma Names William Go, M.D., Ph.D., Chief Medical Officer

    26 Jan 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260126242855/en/Janux-Therapeutics-Appoints-William-Go-M.D.-Ph.D.-as-Chief-Medical-Officer

    BUSINESSWIRE
    26 Jan 2026
    Share Share
    Janux Therapeutics Updates Phase 1 JANX008 Study
    Janux Therapeutics Updates Phase 1 JANX008 Study

    23 Dec 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251223806068/en/Janux-Therapeutics-Provides-Program-Update-on-Ongoing-Phase-1-JANX008-Study

    BUSINESSWIRE
    23 Dec 2025
    Share Share
    Analyst Deems Janux's Stock Spiral An 'Overreaction'
    Analyst Deems Janux's Stock Spiral An 'Overreaction'

    02 Dec 2025

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/janux-t-cell-engager-data-sinks-stock-analysts-still-see-best-class-potential

    FIERCE BIOTECH
    02 Dec 2025
    Share Share
    Janux Reports Positive Results In Phase 1 Trial Of JANX007
    Janux Reports Positive Results In Phase 1 Trial Of JANX007

    01 Dec 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251201540800/en/Janux-Announces-Encouraging-Efficacy-and-Safety-Profile-from-Ongoing-Phase-1-Clinical-Trial-for-JANX007-in-mCRPC

    BUSINESSWIRE
    01 Dec 2025
    Share Share
    Janux Pharma Hosts Virtual Event On JANX007 Clinical Data
    Janux Pharma Hosts Virtual Event On JANX007 Clinical Data

    24 Nov 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251124663993/en/Janux-Therapeutics-to-Host-Virtual-Event-Discussing-Updated-Phase-1a-and-Phase-1b-Clinical-Data-for-JANX007-in-mCRPC

    BUSINESSWIRE
    24 Nov 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search